Previous close | 16.16 |
Open | 16.23 |
Bid | 16.34 x 200 |
Ask | 16.46 x 200 |
Day's range | 15.90 - 16.88 |
52-week range | 15.89 - 41.06 |
Volume | |
Avg. volume | 1,997,288 |
Market cap | 1.995B |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.28 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 39.06 |
PALO ALTO, Calif., April 03, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data from nine studies highlighting advances in methylation-based epigenomic analysis for precision oncology at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 5-10 in San Diego.
In this article, we will be taking a look at the 2o foods to reduce cancer risk. If you do no want learn about the global and US cancer stats, head straight to the 5 Foods To Reduce Cancer Risk. Global and US Cancer Statistics According to data from the World Cancer Research Fund International, […]
A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths. It's already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.